Cases & Deals

  • Home
  • Practices
  • BioMarin acquires Prosensa Holding N.V. for $680 million

Share

BioMarin acquires Prosensa Holding N.V. for $680 million

January 2015

Client(s) BioMarin Pharmaceutical Inc.

Jones Day advised BioMarin Pharmaceutical Inc. in its acquisition of Prosensa Holding N.V., a public, biotechnology company, focused on the discovery and development of RNA-modulating therapeutics for the treatment of rare genetic disorders. The transaction consideration consisted of an up front cash payment of $680 million and achievement of two future regulatory milestones in an aggregate amount equal of $160 million.

In addition to M&A representation, Jones Day provided tax, regulatory, antitrust, employee benefits, and intellectual property advice regarding this transaction.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.